United Laboratories International Holdings Ltd represents a strong commitment to innovation, quality, and customer satisfaction. The company's corporate philosophy revolves around delivering cutting-edge solutions and services to meet the evolving needs of its clients. United Laboratories International Holdings Ltd places great emphasis on integrity, professionalism, and ethical business practices, ensuring the highest standards across all operations. With a focus on research and development, United Laboratories International Holdings Ltd strives to provide top-tier pharmaceutical and healthcare products that improve the well-being of individuals worldwide. This dedication to excellence and customer-centric approach makes United Laboratories International Holdings Ltd a trusted leader in the industry.

United Laboratories International Holdings Ltd is primarily present in various countries and regions. This global pharmaceutical company has a strong presence in the United States, China, Europe, Southeast Asia, and South Africa. With a focus on research and development, United Laboratories International Holdings Ltd has established a robust network in these regions, allowing it to deliver high-quality healthcare products and services. By expanding its reach across different markets, the company aims to meet the diverse needs of patients and healthcare professionals worldwide.

United Laboratories International Holdings Ltd has achieved several significant milestones throughout its history. These milestones include expanding its product portfolio, establishing a strong global presence, and delivering innovative healthcare solutions to millions of people worldwide. The company has successfully launched numerous groundbreaking pharmaceutical and healthcare products, ensuring access to quality healthcare for patients around the globe. Through strategic partnerships and continuous research and development, United Laboratories International Holdings Ltd has consistently demonstrated its commitment to improving the well-being of individuals and communities. These achievements have cemented the company's position as a leader in the healthcare industry.

United Laboratories International Holdings Ltd, commonly known as United Labs, is a renowned pharmaceutical company with a rich history and extensive background. Founded in [insert year], United Labs has emerged as a global leader in the research, development, and manufacturing of innovative healthcare solutions. With a strong emphasis on cutting-edge technology and a dedicated team of experts, the company has consistently delivered high-quality pharmaceutical products that meet stringent international standards. United Labs has a broad product portfolio encompassing various therapeutic areas, including [mention specific areas]. Over the years, the company has expanded its presence globally, establishing strategic partnerships and subsidiaries, thus cementing its position as an industry leader in the pharmaceutical sector.

The main competitors of United Laboratories International Holdings Ltd in the market include big players such as Pfizer Inc., Johnson & Johnson, and Novartis AG. These companies are renowned pharmaceutical giants that compete with United Laboratories International Holdings Ltd in terms of product offerings, market share, and global reach.

United Laboratories International Holdings Ltd is primarily active in the pharmaceutical and healthcare industries.

The business model of United Laboratories International Holdings Ltd (ULI) revolves around the development, manufacturing, and sale of generic and branded pharmaceutical products. As one of the leading pharmaceutical companies in the Asia Pacific region, ULI aims to provide affordable and high-quality healthcare solutions to patients worldwide. With a focus on research and development, ULI continuously strives to innovate and introduce new products to meet the evolving needs of its customers. By adhering to rigorous quality standards and maintaining strong relationships with healthcare professionals, ULI aims to achieve sustainable growth and contribute to the betterment of global healthcare.

United Laboratories International Holdings KGV ir 5,34.

United Laboratories International Holdings KUV ir 0,99.

AlleAktien kvalitātes vērtējums United Laboratories International Holdings ir 8/10.

gaidāmā United Laboratories International Holdings apgrozījums ir 15,09 miljardi CNY.

gaidāmā United Laboratories International Holdings peļņa ir 2,80 miljardi CNY.

United Laboratories International Holdings Ltd (ULIH) is a globally operating company in the chemical and pharmaceutical industry based in Hong Kong. The company offers a wide range of chemical and pharmaceutical products and manufactures them in various divisions distributed worldwide. ULIH's business model is based on comprehensive research and development work that enables the company to produce innovative products that meet customer needs. The pharmaceutical and chemical industry is one of the most important sectors of the global economy today. It is highly dependent on technological developments and investments in research and development. ULIH's position in the global market is supported by offering a variety of high-quality products divided into different categories such as chemical raw materials, semi-finished products, pharmaceuticals, and health products. ULIH produces and distributes raw materials for pharmaceutical production. Such specialty products are often needed in small quantities, making this product segment an important part of the business. The products include medical gases, API (Active Pharmaceutical Ingredients), and injection fluids, among others. In the production of semi-finished products, the company utilizes various technologies and produces targeted active ingredients, cephalosporins, and steroids, for example. In the field of pharmaceuticals, ULIH offers a wide range of medical products such as antibiotics, anti-tuberculosis drugs, analgesics, anti-rheumatics, and others. Some of the well-known products include chloramphenicol and itraconazole. The company's stated goal is to further expand and optimize its medical products to improve the health and well-being of patients worldwide. Another important business area for ULIH is the offering of health products. The offered products include nutritional supplements, herbal extracts, and other products that can contribute to improving the health and well-being of consumers. The company is also committed to a sustainable business model that focuses on environmental aspects, employees, and the common good. It strives to minimize CO2 emissions and create socially responsible working conditions. The brand is valued in many countries around the world and stands out for its quality and customer satisfaction. In summary, ULIH offers a wide range of products and services tailored to the needs of pharmaceutical and chemical companies, health product manufacturers, and end consumers. The business model is focused on continuous improvement and innovation and seeks long-term customer relationships and partnerships.

United Laboratories International Holdings izmaksā dividendes 0,08 CNY, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt United Laboratories International Holdings vai uzņēmums nedod dividendes.

United Laboratories International Holdings ISIN ir KYG8813K1085.

United Laboratories International Holdings WKN ir A0MUFS.

United Laboratories International Holdings simbols ir 3933.HK.

Pēdējo 12 mēnešu laikā United Laboratories International Holdings maksāja dividendes 0,20 CNY apmērā. Tas atbilst aptuveni 2,39 % dividendes ražībai. Nākamajos 12 mēnešos United Laboratories International Holdings plāno maksāt dividendes 0,22 CNY apmērā.

United Laboratories International Holdings pašreizējā dividendu rentabilitāte ir 2,39 %.

United Laboratories International Holdings maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos augusts, oktobris, jūlijs, augusts.

United Laboratories International Holdings pēdējo 9 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0,22 CNY. Tas atbilst dividendes ražībai 2,69 %.

United Laboratories International Holdings tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu United Laboratories International Holdings apmērā 0,132 CNY, kas tika izmaksāta 24.07.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 2.07.2024..

Pēdējās dividendes izmaksa notika 24.07.2024..

Gadā 2023, United Laboratories International Holdings izmaksāja 0,08 CNY dividendes.

United Laboratories International Holdings dividendes tiek izmaksātas CNY.